It remains unclear why the clinically used anti-CTLA-4 antibodies, popularly called
checkpoint inhibitors, have severe immunotherapy-related adverse effects (irAEs) and yet …

A major paradigm in cancer immunotherapy is the use of checkpoint inhibitors to break
regulatory mechanisms that usually guard the host against autoimmune diseases. CTLA-4 …

It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blocking negative
signaling from B7-CTLA-4 interactions. Surprisingly, at concentrations considerably higher …

While immune checkpoint blockade leads to potent antitumor efficacy, it also leads to
immune-related adverse events in cancer patients. These toxicities stem from systemic …

Abstract Anti-CTLA-4 monoclonal antibodies (mAbs) confer a cancer immunotherapeutic
effect (CITE) but cause severe immunotherapy-related adverse events (irAE). Targeting …

Simple Summary Immunotherapy has transformed the treatment of advanced cancers by
leveraging patients' immune system in attacking tumor cells. Cytotoxic T-lymphocyte …

Immune checkpoint inhibitors such as anti–CTLA-4 antibody are widely accepted
therapeutic options for many cancers, but there is still a considerable gap in achieving their …

Monoclonal antibody based immune checkpoint blockade therapies have achieved clinical
successes in management of malignant tumors. As the first monoclonal antibody targeting …

The value of anti-CTLA-4 antibodies in cancer therapy is well established. However, the
broad application of currently available anti-CTLA-4 therapeutic antibodies is hampered by …

CTLA-4 is a crucial immune checkpoint receptor involved in the maintenance of immune
homeostasis, tolerance, and tumor control. Antibodies targeting CTLA-4 have been …